Bitcoin (BTC) can finish the year at $125,000 or more, prediction markets say, as bulls keep up pressure on six figures. Data ...

Shubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer ...

BTC.D nears resistance, signaling potential altcoin outperformance ahead. XLM Leads Gains: Stellar Lumens posts a 122% USD ...

Now that the crypto market has reached a valuation of over $3 trillion, investors are on the lookout for best altcoins to ...

Bitcoin flirts with $100K after SEC Chair Gary Gensler announces resignation. Anthony Pompliano calls the timing "poetic" for ...

Layer-1 blockchain Aptos (APT) has announced a plan to integrate fintech giant Stripe's payment services and the stablecoin ...

If the Senate confirms Bessent, the next person whose signature is on the front of paper U.S. currency will be a fan of ...

Citron said it had hedged its perspective with a short position against MicroStrategy, even though it maintained a positive ...

The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand name Ziihera, it is a first-of-a-kind treatment for patients with ...

The Bitcoin price closed on $100K, but MSTR stock plunged and the Crypto All-Stars presale blasted past $5 million.

On November 22, renowned (and infamous) investor Jim Cramer revealed his bullish stance — now, some are worried that BTC ...

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.